Table 2

Non-ocular adverse events*

Serious non-ocular adverse eventN (%)
All nervous system13 (2.3)
 Cerebrovascular accident3 (0.5)
 Cerebral infarction1 (0.2)
All cardiac30 (5.3)
 Myocardial infarction4 (0.7)
 Acute coronary syndrome1 (0.2)
 Coronary artery occlusion1 (0.2)
 Myocardial ischaemia1 (0.2)
All non-ocular haemorrhagic2 (0.4)
 Haematuria1 (0.2)
Other non-ocular adverse events reported in over 2% of subjects
 Hypertension43 (7.6)
 Urinary tract infection26 (4.6)
 Sinusitis25 (4.4)
 Gastro-oesophageal reflux21 (3.7)
 Pneumonia20 (3.5)
 Benign prostatic hyperplasia10 (4.3)
 Cardiac failure, congestive18 (3.2)
 Bronchitis19 (3.3)
 Nasopharyngitis16 (2.8)
 Headache16 (2.8)
 Nausea15 (2.6)
  • * N=568 subjects with 4254 total injections.

  • Considering only male study population.